Arvinas Reports Q1 Net Loss and Revenue Plunge; Confirms VEPPANU FDA Approval and Commercialization Search

summarizeSummary

Arvinas reported a substantial Q1 2026 net loss and revenue decline, though it confirmed the recent FDA approval of VEPPANU and its ongoing search for a commercialization partner, maintaining its cash runway into H2 2028.

check_boxKey Events

• Significant Revenue Decline

  Revenue for Q1 2026 plummeted to $15.6 million, a substantial decrease from $188.8 million in Q1 2025. The prior year's revenue included a $150.2 million increase from an accounting estimate change related to the Vepdegestrant collaboration.

• Shift to Net Loss

  The company reported a net loss of $57.6 million in Q1 2026, a significant reversal from a net income of $82.9 million in Q1 2025.

• FDA Approval of VEPPANU Confirmed

  As a subsequent event, the FDA granted approval for VEPPANU (vepdegestrant) on May 1, 2026, triggering a $50.0 million development milestone payment from Pfizer, partially offset by payments to Yale University.

• Commercialization Partner Search Ongoing

  Arvinas and Pfizer are still on track to announce the selection of a third party for the commercialization and potential further development of VEPPANU, introducing a new risk factor regarding the success and terms of such a partnership.

auto_awesomeAnalysis

Arvinas reported a significant decline in Q1 2026 revenue and a shift to a net loss, primarily due to a large accounting adjustment that boosted Q1 2025 revenue and a general decrease in collaboration revenue. While the FDA approval of VEPPANU is a major positive, it was announced as a subsequent event and its commercialization strategy remains uncertain as the company seeks a third-party partner. The company's cash runway into the second half of 2028 provides financial stability despite the current cash burn, but the immediate financial performance is weak.